Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FNR9V
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,693
Award facts
- Contract value 100% obligated
- $27,693.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a $27,693.36 firm fixed-price delivery order for Dupixent 300 mg/2 ml pen injections (2 ml) on January 20, 2026, with completion targeted for January 21, 2026. This non-set-aside contract is funded by the Defense Logistics Agency (DLA), which procures medical supplies and pharmaceuticals for the Department of Defense and military healthcare systems. The delivery order was issued under Amerisourcebergen Drug Corp's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 2031, which serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
Dupixent (dupilumab) is a specialty biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic asthma, and other allergic conditions. This delivery order reflects the DLA's ongoing demand for specialty pharmaceutical products to support military treatment facilities and veteran healthcare programs. Amerisourcebergen Drug Corp's extensive federal contract portfolio and demonstrated capability to compete successfully in open market procurement demonstrate the company's established position as a critical vendor within the federal pharmaceutical supply chain for defense-related medical needs.
Quick answers
Who was awarded contract SPE2DR26FNR9V?
SPE2DR26FNR9V was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FNR9V worth?
The government has obligated $27,693 on SPE2DR26FNR9V.
Is contract SPE2DR26FNR9V an order under another contract?
Yes. SPE2DR26FNR9V is a delivery order under SPE2DR25D1021, an indefinite delivery contract.
Was contract SPE2DR26FNR9V competed?
The extent of competition for SPE2DR26FNR9V was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award